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Abstract
Background: India has made great progress towards the elimination of lymphatic filariasis. By 2015, most endemic
districts had completed at least five annual rounds of mass drug administration (MDA). The next challenge is to
determine when MDA can be stopped. We performed a simulation study with the individual-based model LYMFASIM
to help clarify this.
Methods: We used a model-variant for Indian settings. We considered different hypotheses on detectability of
antigenaemia (Ag) in relation to underlying adult worm burden, choosing the most likely hypothesis by comparing the
model predicted association between community-level microfilaraemia (Mf) and antigenaemia (Ag) prevalence levels
to observed data (collated from literature). Next, we estimated how long MDA must be continued in order to achieve
elimination in different transmission settings and what Mf and Ag prevalence may still remain 1 year after the last
required MDA round. The robustness of key-outcomes was assessed in a sensitivity analysis.
Results: Our model matched observed data qualitatively well when we assumed an Ag detection rate of 50 % for
single worm infections, which increases with the number of adult worms (modelled by relating detection to the
presence of female worms). The required duration of annual MDA increased with higher baseline endemicity and
lower coverage (varying between 2 and 12 rounds), while the remaining residual infection 1 year after the last
required treatment declined with transmission intensity. For low and high transmission settings, the median residual
infection levels were 1.0 % and 0.4 % (Mf prevalence in the 5+ population), and 3.5 % and 2.0 % (Ag prevalence in 6–7
year-old children).
Conclusion: To achieve elimination in high transmission settings, MDA must be continued longer and infection levels
must be reduced to lower levels than in low-endemic communities. Although our simulations were for Indian settings,
qualitatively similar patterns are also expected in other areas. This should be taken into account in decision algorithms
to define whether MDA can be interrupted. Transmission assessment surveys should ideally be targeted to
communities with the highest pre-control transmission levels, to minimize the risk of programme failure.
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Background
The fact that humans are the only reservoir host for
lymphatic filariasis (LF), together with the availability of
simple, safe, and inexpensive drugs for treatment and ef-
fective diagnostic tools, led to the recognition that LF
might be eradicable [1]. The Global Programme to Elim-
inate Lymphatic Filariasis (GPELF) was launched in
2000, aiming to eliminate LF as a public health problem
by 2020 [2]. The recommended strategy is to treat entire
at-risk populations annually through mass drug admin-
istration (MDA) with a single dose of ivermectin and
albendazole (IVM+ALB) in sub-Saharan Africa or with
diethylcarbamazine and albendazole (DEC +ALB) in other
regions, including India, for a minimum of 5 years with ef-
fective population coverage of treatment [1, 3].
India has made great progress towards the elimination
of lymphatic filariasis. By 2015, most endemic districts
have completed the WHO recommended minimum of
five annual effective (i.e. at least 65 % treatment coverage)
rounds of MDA with the diethylcarbamazine-albendazole
drug-combination (DEC +ALB) [4]. The key challenge
now is to determine whether this effort has been sufficient
to interrupt transmission, so that MDA can safely be
stopped in all treated areas [5, 6]. In W. bancrofti endemic
areas where the main vector is Anopheles or Culex, the
critical threshold below which MDA can be stopped is as-
sumed to be 1 % for microfilaraemia (Mf) prevalence and
2 % for antigenaemia (Ag) prevalence [3]. Lower values
(0.5 % and 1 %) are proposed for Aedes-transmitted
infection. Five rounds of annual MDA may not always be
sufficient to break transmission, e.g. if coverage is compro-
mised or in settings with the highest transmission inten-
sity. Effective monitoring and evaluation are essential to
assess whether elimination programmes are on track and
whether infection levels have been brought below the crit-
ical threshold.
To monitor whether the Mf and Ag prevalence levels
are declining as expected, the World Health Organization
(WHO) suggests that epidemiological investigations are
done in sentinel and spot check sites. A two-step ap-
proach has been recommended for deciding when to stop
interventions [3, 7]. When a region has completed at least
5 rounds of MDA with sufficient coverage and the Mf or
Ag prevalence in sentinel and spot check sites is shown to
be below 1 % or 2 % respectively, a standardized “Trans-
mission Assessment Survey” (TAS) should be done to
confirm that interventions have reduced the infection
levels below a critical threshold [3]. This involves assessing
the incidence of infection in 6–7 year-old children. This
age-class was chosen because these children already ex-
perience exposure to vector bites, but should have been
protected from LF infection if MDA were successful in
interrupting transmission. The operational feasibility, as-
sumptions and accuracy of TAS have been evaluated in
different endemic settings and the general sampling strat-
egy was proven to be feasible and robust [7, 8]. In India,
besides assessing Mf or Ag-prevalence in sentinel and spot
check sites, Mf-prevalence is determined in 10 randomly
selected sites to decide about conducting TAS [9]. In all
10 sites, Mf-prevalence should be below 1 % for the area
to conduct a TAS. However, questions remain about the
critical thresholds level of infection and the accuracy of
TAS to identify areas that move to elimination or still have
sufficient LF transmission that will cause resurgence of
infection [7].
Mathematical models of lymphatic filariasis transmis-
sion and control provide useful tools to identify the condi-
tions under which elimination could be achieved and to
estimate critical thresholds of infection [10–12]. In this
study, we use the established individual-based model
LYMFASIM [13–17]. This model accounts for several fac-
tors that are critical for predicting elimination through
MDA, including individual heterogeneities in exposure to
mosquito biting and compliance with MDA, stochastic
effects contributing to elimination/recrudescence, and
variability in diagnostic test outcomes in epidemiological
surveys. The purpose of our study is to assess the required
duration of MDA to achieve elimination and the associ-
ated 1-year post-treatment values of Mf and Ag preva-
lence associated with successful elimination, both for the
community as a whole and for 6–7 year children only.
This is done for Indian settings, where Wuchereria ban-
crofti is transmitted by Culex quinquefasciatus, consider-
ing different pre-control endemicity levels.
Methods
The LYMFASIM simulation model
Model structure
LYMFASIM is an individual-based model for simulating
lymphatic filariasis (LF) transmission and control in a
dynamic human population [10, 13, 18]. It employs the
technique of stochastic micro-simulation [19]. The com-
puter program provides a flexible modelling framework,
allowing for the specification of different model variants
by adjusting assumptions and parameter values. Below,
we provide a brief description of main model character-
istics and the simulation of mass drug administration. A
complete mathematical description is provided else-
where [13, 14].
The model simulates a dynamic human population and
transmission of infection between human individuals by a
mosquito population. The human population consists of a
discrete number of individuals and the population com-
position changes over time due to birth, aging and death
of individuals. Humans can be populated by worms (im-
mature or mature, male or female). The lifespan of worms
is described by a Weibull distribution with an average dur-
ation of 10.2 years, independent of the gender of worms.
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The duration of the immature period is fixed at 8 months
for all worms. During their reproductive period, adult fe-
male worms are assumed to produce Mf at a constant rate
(“Mf-production rate”, expressed as the produced number
of Mf per female worm per month per 20 μl of peripheral
blood) if at least one adult male worm is present in the
same host. The mosquito biting rate varies between indi-
viduals, both as a function of age (increasing linearly with
age from a low level to a stable maximum that is reached
at the age of 20) and randomly between individuals (with
an individual’s exposure assumed to be constant over his
lifetime). When a mosquito bites, infection may be trans-
ferred from human to mosquito. Exposure heterogeneity
causes variation in the number of L3 larvae to which indi-
viduals are exposed per month, and hence in the new
worm acquisition rate and resulting accumulated worm
load. Only a small proportion of the L3 larvae that are re-
leased by biting mosquitoes will develop successfully into
adult worms (success ratio), and the success ratio may be
further reduced if a host has acquired protective “anti-L3”
immunity against larvae, as explained further below. The
transmission of infection from human to mosquito is gov-
erned by a non-linear relationship between Mf intensity in
human blood and the average number of infective stage
(L3) larvae that will develop in mosquitoes after taking a
blood meal. The mean infection level in the mosquito
population is derived from the individuals’ Mf density in
the blood and exposure to mosquito bites.
Parameter values of core biological parameters
For the current analysis, we used the “anti-L3 immunity”
LYMFASIM model variant for bancroftian filariasis trans-
mitted by Culex quinquefasciatus as previously developed
by Subramanian et al. [14], with associated derived param-
eter values. (The two other model variants developed by
Subramanian et al. were not considered: the model with-
out immunity failed to explain the age-patterns of infec-
tion, and the anti-fecundity model - which suggests that
moderate Mf prevalence levels in human adults may be
associated with very high prevalence of adult worm - does
not match with our current understanding of the adult
worm biology based on antigen prevalence data.) In the
anti-L3 immunity model, a person’s level of acquired im-
munity is dependent on his cumulative exposure to L3 lar-
vae, and immunity protects against establishment of new
infections by reducing the probability that new larvae sur-
vive to develop into adult worms. The level of protective
immunity varies between individuals due to differences
in past exposure to infection and random variation be-
tween individuals in their ability to develop immunity
against L3 larvae.
The core biological parameters of the model with anti-
L3 immunity were previously quantified by fitting the
model to longitudinal entomological and epidemiological
data from an integrated vector management programme
carried out in Pondicherry, India, from 1981–1986 [14].
The resulting model fitted well to the data, and also pro-
vided accurate estimates of trends in infection prevalence
both before and after cessation of integrated vector man-
agement. We used the same parameter quantification for
the current analysis, simulating settings without integrated
vector management programmes. Only the monthly biting
rate was varied, to have the model represent sites with
different baseline endemicity and transmission conditions.
A complete overview of all model assumptions and
parameter values as used for this study is provided in
Additional file 3.
Assumptions about MDA: coverage, compliance and drug
efficacy
MDA can be simulated at specified time points. In each
round of MDA, a proportion of the total population (de-
fined by the specified coverage) is assumed to be treated
with DEC + ALB, the recommended treatment regimen
for India. Treatment with DEC + ALB was assumed to
kill 70 % of Mf, based on the relative reduction in mean
Mf intensity observed 15–30 days after treatment in
clinical trials (reviewed elsewhere [20]). In addition, we
assumed that treatment kills 65 % of adult worms. A
high macrofilaricidal effect is consistent with the sus-
tained reductions in mean Mf intensity that are seen in
clinical trials [20, 21], and is backed up by evidence from
ultrasonography studies demonstrating a loss of motility
following treatment [22, 23], although uncertainty re-
mains on the quantitative efficacy estimates. Death of
Mf and adult worms was assumed to occur shortly after
treatment (within one month). We further assumed that
there is no inter-individual variation in treatment effects
and that treatment efficacy is independent of the num-
ber of past treatments.
The assumed treatment coverage was varied between
scenarios (50 %, 65 % or 80 %), where coverage is de-
fined as the percentage of people taking treatment (i.e.
swallowing the drug) out of the total population. The
percentage coverage was assumed to be constant over
subsequent rounds of MDA. Individual compliance with
offered treatment was simulated as a partially systematic
process, i.e. it is neither completely random (where each
person has the same chance to get treated in each
round) nor completely systematic (where all individuals
either take all or none of the treatments), but somewhere
in between [24]. The simulated proportion of systematic
non-compliers (i.e. those who never take treatment) for a
given number of treatment rounds is not fixed; it depends
on overall treatment coverage levels; the proportion of
systematic non-compliers in the total population increases
when the overall coverage declines, and vice versa. This
partially systematic process represented the compliance
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pattern of a MDA programme for LF in Tamil Nadu, India
[25] and onchocerciasis in Asubende, Ghana, very well
[24], and we assume that compliance patterns for LF treat-
ment are similar. Variation between age and sex groups in
compliance was not considered.
Simulation output
The model keeps track of changes in infection status
(e.g. number of immature and mature, male and female
worms) at the individual level over time. Simulation out-
put contains the results of simulated epidemiological
surveys, to be performed at user-defined moments (cal-
endar year and month) and three types of output can
be requested: 1) summary output at population level;
2) detailed output at population level by age and sex;
3) individual-level output. The latter provides infor-
mation on the number of male and female worms per
individual, and through further analysis of these output
data the user can derive population-level indicators. For
this study, we were mainly interested on output on Mf
and Ag prevalence by age and sex. We simulated a popu-
lation consisting of 3750 people on average at the moment
of first MDA; the population gradually grows over time
with a rate of 1.9 % per year. The model allows for meas-
urement variation in simulated Mf counts at individual
level, thereby also allowing for false-negative Mf counts.
The presence of antigenaemia is not an explicit part of the
model output, but is derived from output on the presence
of worms based on a hypothesized association between
these two indicators. The first step in this simulation study
was to test three alternative hypotheses for this association
and determine which fits best to empirical data. This is
described further below (step 1 of the simulation study).
Simulation study design
Our study can be distinguished into four different steps:
1) modelling Ag prevalence; 2) estimating the required
duration of mass treatment for achieving elimination;
3) assessing the 1-year post-treatment levels for Mf and
Ag prevalence that are associated with successful elim-
ination; and 4) a sensitivity analysis to assess the effect
of varying treatment efficacy and timing of assessing re-
sidual infection post-MDA.
Step 1: Modelling antigenaemia prevalence
The rapid format immunochromatographic card test
(ICT) for antigen (Ag) detection [26] is now routinely
used in many ongoing elimination programmes for map-
ping, monitoring progress and deciding when to stop
treatment [27]. According to the operational use of Ag
testing, we consider an individual’s Ag status as a binary
outcome, i.e. individuals are either Ag positive or nega-
tive. The detected antigens are thought to originate from
adult Wuchereria bancrofti parasites [28–30] and
antigen tests can demonstrate the presence of adult
worm infection in infected people who do not have de-
tectable Mf levels in their blood (e.g. [31–34]). Other
modellers assumed that any adult worm would always
be detected by the antigen test (as in our hypothesis 1,
see below) [11]. However, there is ample evidence that
the ICT card test sensitivity is less than 100 %, e.g. from
studies demonstrating that antigenaemia can be undetect-
able in men with ultrasound-detected adult worm nests
[35] and from studies showing that the ICT card test de-
tects less infections than other antigen diagnostic tests
such as Og4C3 ELISA [36–38] and the Alere Filariasis
Test Strip [39, 40]. Some uncertainty still remains regard-
ing the exact source of antigens, the relative contribution
of different parasite life stages (male worms, female
worms, Mf) to antigenaemia levels, and the test sensitivity
for the detection of amicrofilaraemic adult worm infec-
tions [41].
In view of prevailing uncertainties, we tested three
hypotheses for the association between antigenaemia
and the presence of adult worms against empirical data,
namely:
 Hypothesis 1: Antigenaemia is assumed to be
detectable if at least one male or female worm is
present in the host, i.e. we have a perfect diagnostic
test with 100 % sensitivity for the detection of all
adult worms;
 Hypothesis 2: The antigenaemia detection rate is
assumed to increase with the number of adult
worms. We simulate this by relating the detectability
of antigenaemia to worm sex, assuming that
antigenaemia is only detected in the presence of at
least one female worm or worm pair; single-sex
infections with male worms only remain undetected.
This is not implausible: male worms may contribute
less to antigenaemia than their female counterparts,
as was observed for a related parasite species
Dirofilaria immitis [41], e.g. due to gender-related
processes or simply the larger size of female worms
[42]. Since male and female worms in our model
occur with the same probability and are independently
distributed over human hosts, linking detectability to
female worms implies that antigens are detected in
50 %, 75 %, 87.5 %, … of individuals infected with
1, 2, 3, … adult worms, and antigenaemia is always
detected in the presence of a male + female worm pair.
 Hypothesis 3: Antigenaemia is detectable only in
the presence of at least one male + female worm
pair. Since the model assumes that all female
worms produce Mf in the presence of a male
worm, antigenaemia would mostly concur with
microfilaraemia (unless a female worm’s fecundity
is reduced by past treatment).
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To test the validity of the three hypotheses, we first com-
pared the model-predicted pre-control association between
Mf and Ag prevalence to data obtained from literature. We
searched the Medline (PubMed) database to identify scien-
tific articles providing pre-control community-level data
on both Mf and Ag prevalence. Studies had to present data
at community level, but we allowed some variation with
respect to the minimum age considered (studies with a
minimum age > 10 years were excluded). We did not im-
pose additional selection criteria concerning the diagnostic
tools used to measure Mf or Ag prevalence. Although our
main interest was in data from the Asian region, we also
included data from other regions (to understand the geo-
graphic stability of the association, and for future usage by
ourselves and others). The literature data are provided in
Additional file 4, along with information on search and
selection criteria. A scatterplot was created to visualize the
association between the two infection indicators in the ob-
served data, for the range of prevalence levels observed in
Asian settings (the observed Mf prevalence seldom exceeds
20 %). Model-predicted values of Mf and Ag prevalence for
the three hypotheses were overlaid on the scatterplot for
visual assessment of the goodness-of-fit of the three hy-
potheses to the empirical data. To capture some of the
between-study variation in the data, model-predictions
were made with varying assumptions regarding diagnostic
test accuracy (reflecting Mf counts by microscopic examin-
ation of either 40 or 60 μl blood, as used in Asian studies)
and resulting prevalences are given either for the whole
population aged 5 years and above, or are age-standardized
to reflect sampling with underrepresentation of children
under 10 and of elderly individuals. Simulations were done
for an average population size of about 3750 individuals
(range 2450–5250 individuals). The goodness of fit of
model to data is visually examined.
As a second step, we tested whether the predicted
antigen prevalence after several rounds of MDA is also
in the right order of magnitude. For this analysis, we
used data on Mf and Ag prevalence from a large-scale
study that evaluated the impact of 8 annual rounds of
MDA in two primary health centres in Thanjavur district
in India. Detailed pre-control data were not available from
this area, but the district was known to be low-endemic.
MDA with DEC alone was given in 1997, 1999, 2000, and
2004; MDA with the combination DEC +ALB was given
in 2001, 2002, 2003, and 2007. Coverage achieved was low
as indicated by both reported and surveyed coverage [8].
The overall Mf prevalence in the district was still 2.6 % in
2000 as observed in sentinel sites, but was reduced to
< 1 % in the 8 sentinel and spot-check sites that have been
surveyed since the 2004 round of MDA; data on Ag preva-
lence were not available from these sites, so we could not
overlay observed data on model-predicted trends in Ag-
prevalence. We tested the model against the detailed data
on Mf and Ag prevalence that were collected in 2008, i.e.
one year after the last round of MDA; the data covered a
total of 80 villages and 15 urban wards [8]. Model parame-
ters were quantified as described above. We fixed the
monthly biting rate at 1600 bites per month per adult
male, a value that was known to result in low baseline en-
demicity in simulated Indian settings. Treatment efficacy
parameters for DEC and DEC +ALB were also fixed at
previously used values [43]. Next, we tuned the overall
treatment coverage (proportion of people treated out of
the whole population) to reproduce the observed post-
treatment overall Mf prevalence levels in the adult popula-
tion after 8 rounds of MDA. In view of the low prevalence
and wide confidence intervals around age-group specific
Mf prevalence, we aggregated the data from the different
communities and wards and we did not aim to reproduce
age-specific Mf prevalence levels exactly. After confirming
that the overall Mf prevalence in adults was adequately
reproduced, we tested whether model-predicted patterns
of Ag prevalence by age were also in agreement with the
data. In view of the many uncertainties involved, we re-
stricted to a qualitative analysis. This was done for each of
the three hypotheses about the association between pres-
ence of parasites and antigenaemia; see Table 1 for more
details regarding the simulated scenarios and used model
outputs. The hypothesis that matched best to data in both
comparisons was taken as our baseline model for predict-
ing Ag prevalence levels.
Step 2: Estimating the required duration of MDA for
eliminating LF
We simulated trends in different infection indicators dur-
ing and after MDA, for four epidemiological settings
varying with respect to mean biting rate and baseline en-
demicity. As baseline prevalence, we took the prevalence
that is achieved after a 130-year warming-up period, and
just before the first round of MDA. A 130-year warming-
up period was necessary to allow the population compos-
ition and endemicity levels to stabilize. Simulations were
done for the Pondicherry setting, for which the model was
originally quantified [14], and three hypothetical settings,
which only differed from Pondicherry with respect to the
monthly biting rates of mosquitoes and hence the endem-
icity levels at baseline. The monthly biting rate (mbr) in
Pondicherry was 2200, corresponding to a pre-control Mf
prevalence of 8.5 % on average. The hypothetical settings
reflected communities with low transmission (mbr = 1600,
mean baseline Mf prevalence 4.9 %), medium transmis-
sion (mbr = 1950, mean baseline Mf prevalence 7.4 %),
and high transmission (mbr = 2700, mean baseline Mf
prevalence 10.0 %). The indicated biting rates are average
biting rates for adults; see Additional file 3 for information
regarding associated biting rates in children and variability
in exposure between individuals). The predicted Mf
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prevalence takes account of measurement variation in Mf
counts and the possible occurrence of false-negative Mf
counts, as would also occur in field situations. We as-
sumed that Mf counts were done by microscopic examin-
ation of a 20-μl thick smear of night finger-prick blood,
and that the variation in Mf counts in blood smears for an
individual follows a negative binomial distribution, similar
to Subramanian et al. [14].
Using similar methods as described elsewhere [17] and
further described below, we determined the minimum
number of MDA rounds that is required to achieve elim-
ination, for each of the four epidemiological settings and
for three levels of treatment coverage (50 %, 65 %, 80 %).
For each of the 12 epidemiological setting-coverage
combinations, we simulated the expected trends in
infection during and after MDA, for different durations
of MDA (1, 2, 3, … rounds), with 1000 repeated runs
per duration to capture the stochastic variations between
runs - all with the exact same input assumptions. We re-
corded for each run whether elimination was eventually
reached and for each scenario (combination of epidemio-
logical setting, coverage and duration) we calculated the
elimination probability per scenario as the percentage of
runs that reached this outcome, with elimination defined
as zero Mf prevalence 60 years after the start of MDA
(and therefore at least 45 years after the last round of
MDA, depending on the simulated number of treatment
rounds). For each of the 12 epidemiological setting-
coverage combinations, the required duration of MDA
was estimated as the lowest number of MDA rounds that
Table 1 Overview of simulated scenarios and simulation outputs considered, by specific objective
Step Specific objective Inputs varied Output considered
1 Comparison of the model-predicted
association between Mf and Ag
prevalence at community level to
observed data from literature
Hypotheses for modelling Ag-prevalence: 1-3 Model-predicted Mf and Ag prevalence for
the population aged 5 years and above, for
each run separatelyMbr: 1500, 1600, 1700, …4000
Comparison of the model-predicted
post-MDA outcomes to empirical data
from Thanjavur district, for the Ag
prevalence by age-group
Hypotheses for modelling Ag-prevalence: 1-3 Model-predicted Mf and Ag prevalence
by age-group, averaged over multiple
repeated runsMbr: 1600
Treatment coverage defined by fitting the
model to observed patterns of Mf prevalence
Efficacy of single treatment with DEC (kills
Mf: 70 % and kills adult worm: 50 %) [87]
Efficacy of single treatment with DEC + ALB
(kills Mf: 70 % and kills adult worm: 65 %) [20]
2 Assess the required duration of MDA
for achieving elimination
Hypotheses for modelling Ag-prevalence: not
relevant for this part of the work
Proportion of runs that resulted in elimination
(elimination was said to occur if the Mf
prevalence was zero, 60 years after the first
treatment round)Mbr: 1600, 1950, 2200, 2700
Treatment duration: varied
Treatment coverage: 50 %, 65 %, 80 %
Efficacy of single treatment with DEC + ALB
(kills Mf: 70 % and kills adult worm: 65 %)
3 Assess the 1-year post-treatment values
for Mf and Ag prevalence associated with
successful control, for the community as
a whole and for 6–7 year children.
Hypotheses for modelling Ag-prevalence:
hypothesis 2 (identified as best in step 1)
Model-predicted Mf and Ag prevalence for
the entire population aged 5 years and above
and for 6–7 year-old children, as measured
1 year after the last treatment roundMbr: 1600, 1950, 2200, 2700
Treatment duration: as need to achieve ≥ 99 %
probability (estimated in step 2)
Treatment coverage: 50 %, 65 %, 80 %
Efficacy of single treatment with DEC + ALB
(kills Mf: 70 % and kills adult worm: 65 %)
4 Sensitivity analysis Hypotheses for modelling Ag-prevalence:
hypothesis 2 (identified as best in step 1)
Model-predicted Mf and Ag prevalence for
the entire population aged 5 years and above
and for 6–7 year-old children, as measured
1 year after the last treatment round, or
6 months or 2 years after treatment
Mbr: 2200
Treatment duration: as need to achieve ≥ 99 %
probability (re-estimated)
Treatment coverage: 65 %
Efficacy of single treatment with DEC + ALB:
varied or as in step 3
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resulted in a ≥ 99 % probability of elimination. For this
part of the simulation study, we only required the follow-
ing simulation output per run: the baseline Mf prevalence
after a 130-year warming-up period (needed to remove
failed runs) and the Mf prevalence 60 years after the first
treatment. Other output was not stored. Failed runs (in
which the parasite population went to extinction during
the warming-up period) were discarded and replaced by
news runs, until we had 1000 successful runs in total per
scenario. Failure only occurred in the low transmission
scenario (mbr = 1600), for about 40 % of the runs.
Step 3. Assessing the residual infection prevalence 1-year
post-MDA after required treatment duration
Next, for each of the 12 epidemiological setting-coverage
combinations, we did a new series of simulation runs
with the number of annual MDA rounds specified as re-
quired to achieve ≥ 99 % probability of elimination.
More output was stored to enable a more detailed as-
sessment of predicted trends in infection and to assess
how much residual infection remained 1 year after the
last annual treatment round. We did 300 repeated runs
per scenario; failed runs were discarded without re-
placing them with new runs, because the number of
remaining successful runs is still sufficient to assess the
frequency distribution. The infection indicators of inter-
est were the simulated Mf and Ag prevalence, for the
population aged 5 years and above and for 6–7 year-old
children, respectively. Ag prevalence was assessed under
the hypothesis that matched best to both types of data
in step 1 of the work.
Step 4. Sensitivity analysis
In a sensitivity analysis, we assessed the influence of
modifying assumptions about (1) treatment efficacy and
(2) the assumed time interval between the last treatment
and the epidemiological assessment. Results are shown
for the Pondicherry setting, assuming 65 % coverage of
MDA. First, we assessed the influence of treatment effi-
cacy assumptions on the required duration of MDA for
achieving elimination and on residual infection levels as
measured one year after the last MDA, both for the Mf
prevalence at community level (population above 5 years
old) and Ag prevalence in 6–7 year-old children. As-
sumptions were modified as follows:
(i) The fraction of adult worms killed due to treatment
was varied at two levels: 50 % and 80 % (versus 65 %
at baseline), while the fraction of Mf killed was kept
at its baseline value (70 %).
(ii) Similarly, the fraction of Mf killed due to treatment
was varied at two levels: 40 % and 100 % (versus
70 % at baseline), while the fraction of adult worms
killed was kept at its baseline value (65 %).
Next, we examined how residual infection levels are in-
fluenced by the time interval between the last treatment
and the epidemiological assessment. The time interval
was halved (6 months) or doubled (2 years). Treatment ef-
ficacy parameters were kept at their baseline values (65 %
adult worm killed, 70 % Mf killed) and the required dur-
ation of MDA was as estimated under step 2.
Results
Modelling antigenaemia prevalence
Figure 1 shows the qualitative level of agreement between
the model-predictions and collated data from literature on
the association between Mf and Ag prevalence at commu-
nity level, for the range of prevalence levels observed in
Asian settings. The number of observations from Asian
settings was limited (black squares), but the empirical as-
sociation is confirmed by observed data from other re-
gions (Africa, Oceania, Americas; open cirles). The model
captures the entire range of observed Mf prevalence levels
in the Asian region. Model-predicted Ag prevalence levels
are generally too high under hypothesis 1 and too low
under hypothesis 3. Hypothesis 2 is most compatible with
the data, even though the predicted prevalence at higher
prevalence levels may be a bit low. The observed data
show considerable variation around the model-predicted
values, which can be explained by sampling variation due
to relatively small sample sizes in the data compounded
by variation in the age-composition of the study sample
and geographic variation in underlying transmission
conditions.
Figure 2 shows the qualitative comparison of model
predictions to observed Mf and Ag prevalence data by
age after 8 rounds of MDA (4 with DEC and 4 with
DEC + ALB). The age-patterns of Mf-prevalence could
not exactly be reproduced, but the absolute level in
adults was adequately matched when we assumed 55 %
treatment coverage per round (Fig. 2a) and this coverage
figure was therefore used for the comparisons shown in
Fig. 2b. Figure 2b shows that hypothesis 1 overestimates
the Ag prevalence in all age-groups, while hypothesis 3
results in a strong underestimation. Predictions obtained
under hypothesis 2 are in the right order of magnitude,
although the levels in adults were somewhat underesti-
mated. The overestimation of Ag prevalence in teenagers
is balanced by the overestimated Mf prevalence in this
age group. Based on the combined results presented in
Figs. 1 and 2, we adopt hypothesis 2 for predicting Ag
prevalence levels in the remainder of the manuscript.
Required duration of MDA for eliminating LF
We considered four epidemiological settings in our simu-
lation experiment, reflecting sites with different mean bit-
ing rates. Details about the endemic situation at baseline
for different endemic settings are shown in Fig. 3. In all
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the settings, the mean predicted Mf prevalence increases
with age with the maximum peak attained at the age of
20 years, followed by a decline up to the age of 39 years
and stabilization at later ages (Fig. 3a). The pattern of age-
specific Ag-prevalence is qualitatively similar in all en-
demic settings (Fig. 3b). As was also shown previously
[14], the predicted age-patterns of Mf prevalence match
well to observed data for Pondicherry. Table 2 shows the
number of annual MDAs needed for achieving ≥ 99 %
probability of infection elimination for different endemic
settings with varying treatment coverages. In the low en-
demic setting, the number of MDAs needed (2–4 rounds)
is fewer than in settings with intermediate (3–7) and high
(4–12) baseline endemicity. The required duration dou-
bles or trebles with decreasing coverage levels for all set-
tings or increasing endemicity: 2–4 rounds of MDA at
80 % coverage to 4–12 rounds with 50 % coverage.
Residual infection prevalence 1-year post-MDA after
required treatment duration
Figure 4 summarizes simulation results with respect to
the Mf and Ag prevalence in the population aged 5 years
and above, prior to MDA and 1 year after the required
treatment duration for elimination. We grouped data by
setting (mbr), irrespective of treatment scenarios, because
the assumed coverage and corresponding treatment dur-
ation did not influence residual infection levels 1 year after
the last treatment if treatment was continued long enough
to achieve elimination, whether achieved by few treatment
with high coverage, or more treatment rounds with lower
coverage (see Additional file 5: Figure S1 for clustered
boxplots by mbr and coverage). Baseline prevalence levels
increased with the assumed biting rate, with the median
Mf prevalence in the population aged 5 years or older in-
creasing from about 5 % for the lowest mbr to 11 % for
the highest value and the Ag prevalence increasing from
about 20 to 30 %, respectively. The prediction intervals for
different mbr levels show considerable overlap. Whereas
the required duration of MDA for achieving ≥ 99 % prob-
ability of elimination increased with mbr (see Table 2), the
residual infection levels associated with this duration and
success probability decreased (panels c and d in Fig. 4, re-
sidual infection measured 1 year after the last MDA round
of the required number). The median residual Mf preva-
lence declined from 1.1 % at the lowest mbr to 0.4 % at
the highest mbr; similarly, the median residual Ag preva-
lence declined from 6.8 % at the lowest mbr to 2.8 % at
the highest mbr. This pattern is as expected: the probabil-
ity that a given residual infection level leads to recrudes-
cence increases with the biting rate. In settings with high
biting rate, infection prevalence must be reduced to very
low levels in order to prevent resurgence, whereas higher
residual levels may remain in sites with low biting rates.
Qualitatively similar patterns were predicted for infection
prevalence in 6–7 year-old children (Fig. 5), except that
the median residual Mf prevalence in this age-group after
Fig. 1 Comparison of the model-predicted association between Mf and Ag prevalence at community level to observed data from literature from
Asian settings (black squares) and other regions including Africa, Oceania and the Americas (open black circles). The scale of the horizontal axis is
restricted based on the observed values from Asian settings. Coloured dots show the model-predicted Mf and Ag prevalence, which were
obtained by varying the average monthly biting rate between 1500–4000 bites per adult person per month. The model predicted Ag
prevalence is shown for three different hypotheses on the mechanistic association between the presence of adult worms and detectability
of antigenaemia. Hypothesis 1: antigenaemia is detectable in the presence of at least one male or female worm (blue). Hypothesis 2: the
Ag detection rate is 50 % for single worm infections, but increases with the number of adult worms, simulated by assuming that antigenaemia
is only detectable in the presence of at least one female worm or worm pair (red). Hypothesis 3: antigenaemia is detectable in the presence of at
least one male + female worm pair (green). The darker and lighter colours show the association if Mf prevalence is measured in 40 and 60 μl blood,
respectively. Simulated prevalence was for the whole population aged 5 years and above (triangles) or was standardized to give the expected
prevalence in a study sample in which children under 10 and elderly individuals (squares) are underrepresented. With these provisions, the model
captures the entire range of observed Mf prevalence levels in Asian settings
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the required number of treatment rounds was zero for all
biting rates. The median residual Ag prevalence in this
group declined from 3.5 % at the lowest mbr to 2.0 % at
the highest.
Red dots in Fig. 4 and Fig. 5 reflect the predicted
values for the few runs that failed to achieve elimination
(the duration was chosen to result in ≥ 99 % probability
of elimination, i.e. up to 1 % of runs did not result in
elimination). The residual infection levels were mostly in
the upper region of the prediction intervals, as would be
expected, but they did not necessarily have the highest
values.
Sensitivity analysis
In our baseline analysis, 5 rounds of MDA with 65 %
would be required to achieve elimination in Pondicherry
(Table 2). The required duration changed to 7 and 4 years,
when we reduced or increased the percentage of worms
killed by a single treatment (50 % or 80 % of worms killed,
versus 65 % in our baseline analysis). The required dur-
ation did not depend on the assumed fraction of Mf killed.
The impact of modified assumptions on the residual Mf
and Ag prevalence is summarized in Fig. 6. In general, the
estimates of residual Mf prevalence post-MDA are more
sensitive to the modification of assumptions than esti-
mates of residual Ag prevalence. Residual Mf prevalence
levels were lower when we assumed lower adult worm
killing per treatment (which in turn was associated with
an increase in the duration of mass treatment needed for
elimination), higher Mf killing, or longer interval between
the last treatment and the epidemiological assessment.
The Ag prevalence in 6–7 year-old children changed in
the same direction, but the impact was much less
pronounced.
Fig. 2 Observed and model predicted age-specific Mf and Ag prevalence post-MDA. Empirical data are from two primary health centres in Thanjavur
district, India, where 8 rounds MDA took place Thanjavur (MDA with DEC alone was given in 1997, 1999, 2000, and 2004; MDA with the combination
DEC + ALB was given in 2001, 2002, 2003, and 2007). The model predictions show expected post-MDA age-prevalence patterns for a setting with low
baseline endemicity (assumed mbr = 1600), with MDA rounds scheduled as in Thanjavur. a Visual qualitative comparison of model predictions to
age-specific Mf prevalence data, under different assumptions for the achieved coverage per treatment round; b Visual qualitative comparison
of model predictions to age-specific Ag prevalence data, under different hypotheses for the association between presence of worms
and antigenaemia
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Discussion
GPELF was initiated with a great sense of optimism that
yearly mass treatment will lead to elimination of LF.
Based on the common assumption that adult worms live
for about 5 years, it was thought that 4–6 yearly mass
treatment would interrupt transmission if a sufficiently
large proportion of the population receives treatment
[21] and 2020 was set as target year for global elimin-
ation. With this target year coming closer, there is in-
creasing demand for model-based policy support of
ongoing elimination programmes, and therefore to fur-
ther improve available models for lymphatic filariasis.
Fig. 3 Age patterns of Mf (a) and Ag (b) prevalence of infection prior to MDA in the four simulated endemic settings. Antigenaemia is assumed
to be detectable if at least one male or female worm is present in the host, but the detection rate increases with the number of adult worms
(hypothesis 2). The model-predicted pattern of Mf-prevalence for Pondicherry (solid red line) matched well to the observed pattern (dots) from
1981. The predicted Mf prevalence prior to MDA at community level (8.5 %) for Pondicherry was within the range of the observed prevalence
(8.6 %; 95 % CI: 7.9–9.4 %), as was the prevalence (5.3 %) in 6–7 year-old children (4.5 %; 95 % CI: 2.3–6.6 %). The model clearly mirrors the
observed decline in prevalence in higher age groups (above 30 years)
Table 2 Number of annual mass treatments required to achieve ≥ 99 % probability of elimination in relation to varying coverage
and MDA
Endemic setting (Monthly biting rate) No. of MDA rounds required at different levels of coverage
50 % 65 % 80 %
Low (1600) 4 2 2
Intermediate (1950) 7 4 3
Pondicherry (2200) 8 5 3
High (2700) 12 6 4
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With this vision, three groups hitherto working independ-
ently on LF models started to collaborate as members of
the Modelling Consortium for Neglected Tropical Dis-
eases [44]. The consortium published a collection of pa-
pers in this journal, describing the different models for LF
[11, 12] and other NTDs [45]. The current manuscript is
part of this collection.
In this study, we used the stochastic microsimulation
model LYMFASIM to study how the time to elimination
and post-MDA residual infection levels depends on average
biting rates (resulting in different baseline endemicity levels)
and the achieved coverage in MDA programmes. The
model takes account of inter-individual heterogeneities,
e.g. in exposure to mosquitoes or compliance with offered
treatment, which is known to influence the effectiveness
of population-based control measures and the probability
of elimination [46].
Association between presence of infection and
antigenaemia
The addition of antigenaemia as new output to the
LYMFASIM model is a pre-requisite for broader use of
the model to guide country elimination programmes and
help refine decision algorithms used to define when
MDA can be stopped safely, because antigen detection
has become the preferred diagnostic tool for use in TAS
[3]. We tested multiple hypotheses about the mechanistic
association between adult worm and antigenaemia pres-
ence in individuals against data (Figs. 1 and 2). Figure 1
compared the model-predicted association between Mf
and Ag prevalence to observed pre-control data collated
from the literature. In this selection we observed a higher
correlation but otherwise very similar association between
the two infection indicators as demonstrated by Cano
et al., who based their analysis on a different selection
of data [47]. Cano et al. excluded Og4C3-ELISA-based
Ag prevalence estimates and included more data from
national control programmes (obtained under less well
standardized conditions than study data), which may have
contributed to the lower correlation between the two in-
fection indicators.
While the antigens derive from adult worms, our com-
parison of model predictions to data suggests that anti-
gen tests detect only part of the adult worm infection.
We tentatively related the detectability of antigenaemia
to worm sex, assuming that the contribution of male
worms to antigenaemia concentrations may be smaller
than that of female worms. The assumption that infec-
tions with male worms only remain undetected is
perhaps biologically plausible, considering the much
Fig. 4 Predicted Mf and Ag prevalence for the population aged 5 years and above, prior to MDA (a & b) and 1 year after the required treatment
duration (c & d). Antigenaemia is assumed to be detectable if at least one male or female worm is present in the host, but the detection rate
increases with the number of adult worms (hypothesis 2). The boxes show the 25th and 75th percentiles of the distribution of the prevalence
values and the horizontal line across the box is the median prevalence. The whiskers extend to 1.5 times the height of the box (i.e. the interquartile
range, IQR) or, if no case/row has a value in that range, to the minimum or maximum values. If the data are distributed normally, approximately 95 %
of the data are expected to lie between the inner fences. Values more than three IQR’s from the end of a box are labelled as extreme, denoted with
an asterisk (*). Values more than 1.5 IQR’s but less than 3 IQR’s from the end of the box are labelled as outliers (o). The boxes combine information
from the ~99 % runs ending in elimination and the ~1 % runs that did not achieve the target. The red dots indicate the prevalence levels for the few
runs that did not result in elimination
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smaller size of male worms and presumably much
smaller contribution to antigen concentrations in the
blood [42], but is not proven by the current analysis.
However, through this assumption we capture an im-
portant feature, namely the likely association between
the host’s adult worm load and antigen detection rate.
In our model, the probability of having a single-sex in-
fection declines with increasing worm loads, and there-
fore the antigen detection rate increases with worm
burden (on average antigens are detected in 50 %, 75 %,
87.5 %, … of people carrying 1, 2, 3, … worms, respect-
ively). Qualitatively, this in line with empirical data sug-
gesting imperfect sensitivity by comparing outcomes of
different diagnostic tests especially at low worm loads
[35, 36, 38, 39].
A limitation of the current implementation of hy-
pothesis 2, is the lack of an explicit sensitivity param-
eter that could be used to mimic different types of
antigen tests. A more flexible and potentially more real-
istic approach to model antigenaemia mechanistically
would involve explicit, quantitative simulation of anti-
gen concentrations in the blood. Assumptions would
have to be made regarding the relative contribution of
various parasite stages to this concentration and the de-
tection threshold, as has been done for modelling anti-
gen levels for schistosomiasis [48]. Test sensitivity
could easily be adjusted for different types of Ag detec-
tion test (e.g. for ICT vs Alere) by assuming a higher or
lower detection threshold. If the detection threshold is
in the same order of magnitude as the contribution
coming from one female worm, while assuming a much
lower contribution from male worms and no contribu-
tion from Mf, this quantitative model is comparable to
our hypothesis 2.
The comparison of model predicted Ag prevalence
levels to data in this study suggest that hypothesis 2
might provide a crude but not unreasonable approxima-
tion of the more complex model, whether detection is
mediated by worm sex or not. Yet, the hypothesis should
be tested more extensively, using different model vari-
ants (such as LYMFASIM’s model variant for Africa [16]
which does not include a role for acquired immunity
and results in considerably higher prevalence levels) and
data from other regions. It will be interesting to study
whether this hypothesis also accurately predicts Ag
prevalence levels as would be found with the new Alere
Filariasis Test Strip, which was found to detect more in-
fections [39, 40].
Required number of treatment rounds
The required number of treatment rounds for achieving
elimination was found to increase with baseline endem-
icity (as proxy for local transmission conditions) and with
lower treatment coverage. For instance, in low endemic
settings, the number of rounds could be as low as 4 or 2
with a treatment coverage of 50 % or 80 % when com-
pared to that of high settings (12 rounds or 4 rounds).
This is in line with our earlier reports, also for other set-
tings [15, 17], and predictions from other models [10, 49].
Estimates of the absolute number of rounds required
Fig. 5 Predicted Mf and Ag prevalence for 6–7 year-old children, prior to MDA (a & b) and 1 year after the required treatment duration (c & d).
Antigenaemia is assumed to be detectable if at least one male or female worm is present in the host, but the detection rate increases with the
number of adult worms (hypothesis 2). See legend to Fig. 4 for additional information regarding the interpretation of the boxplots
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should be interpreted with care, because they depend on
(often unknown) local transmission conditions and uncer-
tain model assumptions [12, 50–52]. Stolk et al. [17]
showed how the predicted required duration depends on
the assumed efficacy of treatment on adult worms. If the
macrofilaricidal effect in reality would be lower than as-
sumed here, the total number of treatment rounds needed
to achieve elimination would increase, and vice versa.
Residual infection prevalence after MDA
TAS with standardized methods are recommended to
verify that elimination is achieved in an area under
evaluation. When the community Mf prevalence in sen-
tinel and spot-check sites is shown to be below 1 %, TAS
is recommended to verify that the average Ag prevalence
in 6–7 year-old children is significantly lower than the
threshold value of 2 % [3]. We estimated acceptable re-
sidual Mf and Ag prevalence levels as the levels associ-
ated with 99 % probability of elimination and found that
the range of acceptable values extends well above the
threshold, suggesting that the proposed threshold is
probably safe for most settings to verify for individual
communities whether elimination is achieved.
The acceptable residual infection levels were found to
decrease with increasing baseline endemicity or biting rate
(Figs. 4 and 5). In settings with low baseline endemicity, a
higher residual Mf and Ag prevalence may remain post-
treatment, because the low biting rate prevents resurgence
of transmission. This pattern is theoretically expected [46]
and in line with predictions from other models for oncho-
cerciasis and lymphatic filariasis [12, 51, 53]. The levels
were independent of the achieved coverage in mass treat-
ment. Although our predictions were for Indian settings
only, qualitatively similar patterns are expected regions
with other parasite-vector combinations. Considering the
negative association between biting rate or baseline endem-
icity and acceptable residual infection prevalence, it is espe-
cially important to confirm that the 2 % threshold is low
enough to distinguish between success and failure of elimin-
ation programmes even in high-transmission settings. This
requires additional simulation work to estimate the prob-
ability of elimination in relation to the one-year post-MDA
residual infection levels and local transmission conditions.
Uncertainty in model predictions
Care is required in the interpretation of our results. Un-
certainty is inherent in the model-estimated required dur-
ation and acceptable post-treatment infection levels and
care is required in the interpretation of the presented
numbers. Whether or not a certain residual infection level
Fig. 6 Sensitivity analysis: impact of modified assumptions on the residual Mf (a) and Ag (b) prevalence that is expected if MDA is continued long
enough to achieve elimination with ≥ 99 % probability. See legend to Fig. 4 for additional information regarding the interpretation of the boxplots
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will move the parasite population to extinction or recru-
descence, depends on the probability that a worm can mate
and successfully reproduce, which in the model is driven by
assumptions regarding local transmission intensity, density-
dependent processes involved in the transmission, the de-
gree of parasite over-dispersion among hosts in the popula-
tion, and the interactions of these with the intervention(s)
deployed [46, 50, 51, 53, 54]. Our model captures many of
the relevant processes, e.g. variation in exposure to mos-
quito bites, density dependence in transmission from
human to vector (limitation in Culex quinquefasciatus,
facilitation for Anopheles mosquitoes [55–58]) and from
vector to human (acquired immunity [14, 59, 60]), and vari-
ation between individuals in compliance with treatment
[46, 50, 53, 54]. Yet, our qualitative understanding of these
processes is still incomplete, which is exemplified by the
debated role of acquired immunity [60]. Also, empirical evi-
dence for quantification of these processes is limited. Better
qualitative and quantitative understanding of these pro-
cesses is key to improve the accuracy of critical threshold
levels, which will require multidisciplinary approaches,
combining knowledge and methods from entomology,
biology, epidemiology, mathematics [54].
More work is also needed to understand better how
transmission conditions and model parameters can vary
between sites and over time, and thus to what extent
our findings can be generalized to other settings even if
the vector-parasite complex is the same. We simulated
hypothetical Indian communities with pre-defined mean
exposure and patterns of exposure, under the assump-
tion that model-parameters remain stable over time.
While the assumption of geographical and time-stability
may seem reasonable for core biological parameters (e.g.
related to the parasite lifecycle or host immunity), it is not
impossible that some of these parameters change with the
hosts’ nutritional or co-infection status. Exposure-related
parameters are likely more amenable to variation in space
and time. They depend on climatological factors and en-
vironmental conditions driving the presence of breeding
sites and abundance of mosquitoes, and on the use of
personal protection measures (such as window screens,
bednets); these parameters in turn are influenced by eco-
nomic development and likely to change over time. Care
is therefore required in the interpretation of long-term
predictions and in translating the findings to other specific
settings. Other modelling studies indeed confirm that par-
ameter values vary between sites, but parameter values
seem to be relatively stable over the typical duration of
MDA programmes [12, 52, 61].
Implications of heterogeneity for elimination
programmes
Our results demonstrate how required duration of
MDA and post-MDA residual infection levels depend
on local transmission conditions and achieved coverage.
We did not assess the validity of the full TAS method-
ology, in which average Ag prevalence in children is
assessed in cluster or systematic sample of children
from different communities and which also involves re-
peated assessments several years after stopping MDA.
Nevertheless, our results help to illustrate the potential
implications of heterogeneity between communities in
the evaluation area.
If we assume that all communities within an evalu-
ation area are similar with respect to local transmission
conditions (mbr) and operational effectiveness of MDA
(number of treatment rounds, coverage and compliance
patterns), then the individual boxes in the lower panels
of Figs. 4 and 5 show what distribution of residual infec-
tion levels would be consistent with ≥ 99 % probability of
elimination. However, heterogeneity in transmission con-
ditions and effectiveness of MDA is to be expected within
an evaluation area, which might cover over 1000 commu-
nities and a population size up to 2 million people. MDA
should be continued long enough to ensure that elimin-
ation is expected even in communities with highest trans-
mission intensity and lowest coverage. In addition, the
critical threshold used to determine whether MDA can
stop should be set low enough to ensure successful elim-
ination in the communities with highest transmission in-
tensities. If the threshold is reached in these communities,
it is likely that other communities with less intensive
transmission have also achieved their threshold (which
would be higher, and expected to be achieved in fewer
rounds). This implies that, for many communities in that
region, MDA would be continued longer than strictly re-
quired, resulting in lower residual infection levels than
shown in the boxplots.
Rather than ensuring that the average level of residual
infection in the area is below a threshold, TAS should be
designed to minimize the risk that pockets with unaccept-
ably high residual infection levels remain after cessation of
MDA. Ideally, TAS should be targeted at the sites with the
most unfavourable conditions for elimination (highest bit-
ing rates and lowest coverage). Failure to include such
villages may falsely suggest that the critical threshold is
achieved everywhere and lead to premature cessation of
the elimination programme, local recrudescence of tran-
smission, and eventually reintroduction of infection in
surrounding areas. It is therefore crucial to identify these
settings, based on community-level predictors of high
transmission intensity, poor coverage and poor compli-
ance. Predictors for high transmission intensity could in-
clude geographical and environmental factors (e.g. climatic
conditions, altitude, vegetation, altitude, population density
[47, 62–65], health system and epidemiological features
(e.g. bednet coverage [66]), history of mass ivermectin
treatment [67, 68]) and socio-economic and sanitary
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conditions [47]. Possible predictors of poor coverage and
compliance include health system and programmatic fac-
tors (e.g. drug distribution system, number of drug distrib-
utors per population, training of distributors, sensitization
of the population for MDA, immunization rate [69–74]),
geographic factors (e.g. remoteness, level of urbanization
[75–77], and demographic factors (population size, migra-
tion, population density [71, 78]).
This study showed that sites with very high biting rates
present a particular challenge to elimination programmes.
These settings could benefit from vector control, as an ad-
junct to MDA, which is expected to reduce the duration
of control [11, 52]. Adding integrated vector management
would help to homogenize the transmission conditions
within an evaluation unit within a region and to minimize
the risk that pockets with ongoing transmission remain
after cessation of MDA. This will, however, increase the
overall costs of the programmes but with multiple collat-
eral benefits.
Prospects for LF elimination by 2020
The Global Programme to Eliminate Lymphatic Filariasis
was set up with the aim to eliminate LF globally by
2020. Great progress has been made: as of 2014, 39 of
the 73 endemic countries have implemented MDA; 46
countries have completed 5 or more MDA rounds. Of
them, 18 countries have already stopped MDA and pro-
gressed to the surveillance phase, with 55 countries con-
tinuing to require MDA. Eleven countries have yet to
start MDA [79]. Although the global programme to
eliminate LF has been successful to date, It has been rec-
ognized that coverage will have to be scaled up substan-
tially if the 2020 target is to be achieved [80].
In India, LF is endemic in 255 districts from 20 States/
Union Territories, with a total of about 600 million people
at risk. By 2015, most endemic districts had completed the
five annual rounds of mass drug administration (MDA)
with the diethylcarbamazine-albendazole drug-combination
(DEC+ALB), with good reported coverage. Mf prevalence
surveys performed in sentinel and spot check sites suggest
that the overall Mf prevalence in endemic areas has been
reduced from 1.24 % in 2004 to about 0.3 % in 2013, and
about 200 districts have reported overall Mf prevalence
levels < 1 % [81]. However, much heterogeneity is to be ex-
pected, both in baseline endemicity levels (known to vary
between districts and communities [60, 82] and in achieved
coverage. Reported coverage seems adequate, but there is
great concern about the gap between the number of tablets
distributed and the actual ingestion of the drugs [83]. As
shown in this paper, both factors influence the required
duration of MDA for achieving elimination. Several epi-
demiological studies confirmed that infection may persist
after long-term MDA [84–86], with spatial clustering in
hotspots with potential for resurgence of infection. The
large size of implementation units implies that there is huge
potential for hotspots to remain undetected in pre-TAS
and TAS surveys. Better targeting of TAS to sites expected
to have high transmission potential or low achieved cover-
age would help to reduce this risk.
Conclusions
Our simulation study provided plausible ranges of required
post-treatment values for Mf and Ag prevalence, at com-
munity level as well as for children of 6–7 year-old, which
are associated with ≥ 99 % probability of elimination in
Indian settings, where parasite W. bancrofti is transmitted
by the vector Cx. quinquefasciatus. The TAS requires that
the Ag prevalence in 6–7 old children is brought below
2 %, and this threshold falls well below the upper level of
the range of predicted infection levels associated with
≥ 99 % probability of elimination. The acceptable level of
residual Mf prevalence was found to substantially decrease
with increasing baseline endemicity. Qualitatively similar
patterns are expected in other regions. In practice therefore,
the critical threshold should be chosen low enough to also
result in elimination in high endemic settings. To ensure
the achievement of elimination throughout an evaluation
area, TAS should be targeted at the sites with the highest
transmission intensity and lowest coverage.
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